MetaCap

Arbutus Biopharma (ABUS) vs Olema Oncology (OLMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arbutus Biopharma (ABUS) has outperformed Olema Oncology (OLMA) over the past year, losing 6.7% versus a loss of 69.7%. Over five years, ABUS leads with a +28.4% price change compared with -66.4% for OLMA. Arbutus Biopharma is the larger company by market cap ($616.2 million vs $615.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABUS-6.73%OLMA-69.70%
+61%-9%-79%
Nov 21, 20251 yearNov 20, 2026
ABUS+21.82%OLMA-69.16%
+65%-16%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABUS versus OLMA key metrics
MetricABUSOLMA
Share price$4.02$7.02
Market cap$616.24M$615.00M
1-day change-1.23%-1.82%
YTD return-16.42%-71.92%
1-year return-6.73%-69.70%
5-year return+28.43%-66.36%
P/E ratio (TTM)3.59—
EPS (TTM)$1.12$-2.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.08M—
Revenue growth (YoY)+128.21%—
Net income (latest FY)$-33.50M$-162.45M
Operating margin-270.96%—
Net margin-237.88%—
52-week high$5.45$36.26
52-week low$3.50$6.24
Distance from 52-week high-26.24%-80.64%
Analyst consensusnonestrong_buy
Avg. price target upside+32.34%+405.70%
Average volume4.98M1.27M
Shares outstanding153.29M87.61M
Employees19131
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ABUS has outperformed OLMA by 63.0 percentage points over the past year.

About Arbutus Biopharma

ABUS stock →

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

About Olema Oncology

OLMA stock →

Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees

ABUS vs OLMA FAQ

Which is bigger, Arbutus Biopharma or Olema Oncology?

Arbutus Biopharma (ABUS) is larger, with a market capitalization of $616.24M compared with $615.00M for Olema Oncology (OLMA).

Which stock has performed better over the past year, ABUS or OLMA?

ABUS returned -6.73% over the past 12 months, compared with -69.70% for OLMA (price return, excluding dividends). Past performance does not predict future results.

Are Arbutus Biopharma and Olema Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons